Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Arzerra

02 4Kesimpta

PharmaCompass

01

Brand Name : Kesimpta

Ofatumumab

arrow
Antibody Engineering
Not Confirmed

Brand Name : Kesimpta

arrow
Antibody Engineering
Not Confirmed

Ofatumumab

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 15

2019 Revenue in Millions : 0

Growth (%) : New Launch

blank

02

Brand Name : Kesimpta

Ofatumumab

arrow
Antibody Engineering
Not Confirmed

Brand Name : Kesimpta

arrow
Antibody Engineering
Not Confirmed

Ofatumumab

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 372

2020 Revenue in Millions : 15

Growth (%) : 2,380

blank

03

Brand Name : Kesimpta

Ofatumumab

arrow
Antibody Engineering
Not Confirmed

Brand Name : Kesimpta

arrow
Antibody Engineering
Not Confirmed

Ofatumumab

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 1,092

2021 Revenue in Millions : 372

Growth (%) : 194

blank

04

Brand Name : Kesimpta

Ofatumumab

arrow
Antibody Engineering
Not Confirmed

Brand Name : Kesimpta

arrow
Antibody Engineering
Not Confirmed

Ofatumumab

Main Therapeutic Indication : Neurology

Currency : USD

2023 Revenue in Millions : 2,171

2022 Revenue in Millions : 1,092

Growth (%) : 99

blank

05

Brand Name : Arzerra

Ofatumumab

arrow
Antibody Engineering
Not Confirmed